The Federal Trade Commission (FTC) and Alaska, Iowa, Nebraska, and Texas (all red states) have joined forces to sue the World Professional Association for Transgender Health (WPATH), alleging that it made deceptive claims about the safety and effectiveness of pediatric gender-affirming medical treatments. The lawsuit argues that WPATH overstated evidence that supports interventions such as puberty blockers and hormone therapy, while minimizing potential risks, misinforming physicians, parents, and insurers. WPATH denies these allegations and maintains that its standards of care are backed by scientific expertise. WPATH contends that the lawsuit is politically motivated, pointing out that “the U.S. Federal Trade Commission is not a medical provider and has no place interfering with the process of individualized medical decision-making…”. This litigation is part of a broader effort by the Trump administration to challenge and restrict pediatric gender-affirming care, something the American public has also grown more supportive of in recent years. We will be following this case closely to see how these allegations play out in court.
FTC Claims Trans Medicine is Consumer Fraud
